HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: Overall, these findings indicated that quinacrine and the HDAC inhibitor chidamide have a synergistic antitumor effect on PTCL, suggesting a novel therapeutic strategy for treating this genetically heterogeneous disease.